<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4871">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01907802</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-01338</org_study_id>
    <secondary_id>NCI-2013-01338</secondary_id>
    <secondary_id>MC1211</secondary_id>
    <secondary_id>9343</secondary_id>
    <secondary_id>U01CA132123</secondary_id>
    <secondary_id>U01CA069912</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT01907802</nct_id>
  </id_info>
  <brief_title>Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction</brief_title>
  <official_title>A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients With BRAFV600X Mutations and Renal or Hepatic Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and the best dose of dabrafenib in treating
      patients with solid tumors and kidney or liver dysfunction. Dabrafenib may stop the growth
      of tumor cells by blocking some of the enzymes needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the toxicity profile and the maximum tolerated doses (MTDs) of dabrafenib in
      patients with v-raf murine sarcoma viral oncogene homolog B1 (BRAF)^V600X mutations and
      renal or hepatic dysfunction.

      SECONDARY OBJECTIVES:

      I. To assess for tumor response and various times to clinical event. II. To provide dosing
      recommendations for dabrafenib in patients with varying degrees of hepatic and renal
      dysfunction for possible inclusion in the label.

      TERTIARY OBJECTIVES:

      I. To assess the pharmacokinetic and pharmacogenetic profile of dabrafenib and active
      metabolites.

      OUTLINE: This is a dose-escalation study.

      Patients receive dabrafenib orally (PO) twice daily (BID) on days 1-28 (once daily [QD] on
      day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of toxicities graded according to NCI CTCAE v4.0</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overall toxicity incidence as well as toxicity profiles by dose level and patient will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD of dabrafenib, defined as the highest dose level that is estimated to induce a dose-limiting toxicity (DLT) rate less than 33.3% by the two-way isotonic regression, graded according to NCI CTCAE v4.0</measure>
    <time_frame>Up to 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overall toxicity incidence as well as toxicity profiles by dose level and patient will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events graded according to NCI CTCAE v4.0</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number and severity of all adverse events (overall, by dose level, and by tumor group) will be tabulated and summarized for the three patient groups. The grade 3+ adverse events will also be described and summarized in a similar fashion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response, defined as the best objective status recorded from the start of treatment until disease progression/recurrence, measured by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until any treatment-related toxicity</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The data on time-related variables will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until treatment related grade 3+ toxicity</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The data on time-related variables will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until hematologic nadirs (white blood cells [WBC], ANC, platelets)</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The data on time-related variables will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The data on time-related variables will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Time from registration to documentation of progression, unacceptable toxicity, or refusal to continue participation by the patient, assessed up to 30 days after completion of study treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The data on time-related variables will be summarized descriptively.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic profile of dabrafenib</measure>
    <time_frame>Days 1 and 15 of course 1, and day 1 of all subsequent courses</time_frame>
    <safety_issue>No</safety_issue>
    <description>Descriptive statistics and statistical plots will form the basis of presentation of biomarker, pharmacokinetic and pharmacogenetic studies. Clinical response and toxicity profile for patients will be correlated with the pharmacokinetic (PK) parameters and key polymorphisms in gene.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacogenetic profile of dabrafenib</measure>
    <time_frame>Day 1 prior to treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Descriptive statistics and statistical plots will form the basis of presentation of biomarker, pharmacokinetic and pharmacogenetic studies. Clinical response and toxicity profile for patients will be correlated with the PK parameters and key polymorphisms in gene.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Hepatic Complications</condition>
  <condition>Renal Failure</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (dabrafenib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dabrafenib PO BID on days 1-28 (QD on day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabrafenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (dabrafenib)</arm_group_label>
    <other_name>BRAF inhibitor GSK2118436</other_name>
    <other_name>GSK-2118436A</other_name>
    <other_name>GSK2118436</other_name>
    <other_name>Tafinlar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (dabrafenib)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (dabrafenib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PRE-REGISTRATION ELIGIBILITY CRITERIA

          -  Willing to provide tissue as required per protocol for central BRAF-V600 mutation
             testing

               -  NOTE: Patients with prior BRAF testing that demonstrate a mutation at V600 will
                  be allowed to enroll prior to central testing if the assay was performed at a
                  Clinical Laboratory Improvement Amendments (CLIA)-certified lab using the COBAS,
                  Pyromark BRAF, Karmonos Detroit Medical Center-University Laboratories (DMC)-UL
                  BRAF, THxID BRAF or Response Genetics BRAF assays; if the assay was based on
                  other methodology other than COBAS, Pyromark BRAF, Karmonos DMC-UL BRAF, THxID
                  BRAF or Response Genetics BRAF assays, the results should be confirmed by
                  central lab testing prior to patient enrollment; should central testing prove to
                  be discordant with initial result (wild-type, non-mutated BRAF), patient will be
                  allowed to continue on study at the discretion of the investigator

          -  Patients with unknown BRAF status: histologically confirmed melanoma, papillary
             thyroid, cholangiocarcinoma or testicular cancer that is metastatic or unresectable
             and for which the investigator feels a BRAF targeted agent is a reasonable treatment

               -  NOTE: patient must be screened by central BRAF testing and must demonstrate a
                  V600 mutation prior to start of study agent

               -  Note: other tumor types without known BRAF mutations will not be eligible for
                  central testing

          -  Ability to understand and willingness to sign written informed consent

          -  Life expectancy of &gt; 3 months

          -  REGISTRATION ELIGIBILITY CRITERIA

          -  Patients with known BRAF-V600 mutation: patients must have BRAF-V600 mutated,
             histologically confirmed cancer that is metastatic or unresectable and for which
             curative or standard therapies do not exist or are no longer effective

               -  NOTE: Colorectal cancers with BRAF mutations ARE NOT allowed

               -  NOTE: Any mutation at the V600 position that results in a change from V (valine)
                  is allowed; this includes E, D, K, R or other mutations not noted here at the
                  V600 position

          -  Any number of the following prior therapies is allowed:

               -  Chemotherapy &gt;= 28 days prior to registration

               -  Mitomycin C/nitrosoureas &gt;= 42 days prior to registration

               -  Immunotherapy &gt;= 28 days prior to registration

               -  Biologic therapy &gt;= 28 days prior to registration

               -  Radiation therapy &gt;= 28 days prior to registration

               -  Radiation to &lt; 25% of bone marrow

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky &gt;=
             70%)

          -  Able to swallow and retain oral medication

          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L

          -  Hemoglobin &gt;= 9 g/dL

          -  Platelets &gt;= 75 x 10^9/L

          -  Hepatic and renal function meeting one of the strata below:

               -  Group N: Hepatic: normal function (bilirubin =&lt; upper limit of normal [ULN];
                  aspartate aminotransferase [AST] =&lt; ULN); Renal: normal function (creatinine
                  clearance [CrCl] &gt;= 60 mL/min)

               -  Group R3: Hepatic: normal function (bilirubin =&lt; ULN; AST =&lt; ULN); Renal: severe
                  dysfunction (CrCl &gt;= 15 and &lt; 30 mL/min)

               -  Group R4: Hepatic: normal function (bilirubin =&lt; ULN; AST =&lt; ULN; Renal: renal
                  failure (hemodialysis)

               -  Group H1: Hepatic: mild dysfunction (bilirubin =&lt; ULN; AST &gt; ULN); Renal:
                  acceptable function (CrCl &gt;= 60 mL/min)

               -  Group H2: Hepatic: moderate dysfunction (bilirubin &gt; ULN and =&lt; 3 x ULN; AST &gt;
                  ULN); Renal: acceptable function (CrCl&gt;=â‰¥ 60 mL/min)

               -  Group H3: Hepatic: severe dysfunction (bilirubin &gt; 3 x ULN and up to
                  investigators discretion; AST &gt; ULN); Renal: acceptable function (CrCl &gt;= 60
                  mL/min)

          -  Women of childbearing potential must have a negative serum pregnancy test =&lt; 7 days
             prior to registration

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (barrier method of birth control; abstinence) prior to study entry and for the
             duration of study participation; should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately; men treated or enrolled on this protocol must
             also agree to use adequate contraception prior to the study, for the duration of
             study participation, and 1 month after completion of dabrafenib administration

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Willingness to provide to provide blood and tissue samples as required per protocol

          -  Patients with a history of clinical benefit from prior RAF inhibitor therapy, as
             judged by the investigator, will be allowed

        Exclusion Criteria:

          -  Patients with active biliary obstruction; NOTE: patients for which a shunt has been
             in place for at least 10 days prior to the first dose of dabrafenib are allowed

          -  Reduced left ventricular ejection fraction (&lt; 50%) or other evidence of cardiac
             dysfunction as determined by the investigator

          -  Use of an investigational anti-cancer drug within 28 days preceding the first dose of
             dabrafenib

          -  Patients receiving any medications or substances that are strong inhibitors or
             inducers of cytochrome P450, family 3, subfamily A (CYP3A) or cytochrome P450 family
             2, subfamily C, polypeptide 8 (CYP2C8) are ineligible

               -  For patients on intermediate inducers or inhibitors, attempts should be made to
                  switch to an alternative agent or delay enrollment until treatment course with
                  concomitant agent completed; if not possible, patient may be enrolled if it is
                  felt to be in the patients best interest as decided by the investigator

               -  Weak inhibitors of CYP3A or CYP2C8 should be used with caution and attempts made
                  to limit their use or find alternative agents, if possible

          -  Warfarin use is provisionally allowed

          -  Unresolved toxicity of National Cancer Institute Common Terminology Criteria for
             Adverse Events, version 4.0 (NCI CTCAE v4.0) grade 2 or higher from previous
             anti-cancer therapy, except alopecia

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible; Note: patients not on antiretroviral therapies are eligible
             for this study

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, diabetes mellitus, hypertension, symptomatic congestive heart failure,
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
             situations that would limit compliance with study requirements

          -  Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

          -  Presence of malignancy other than the study indication under this trial within 5
             years of study enrollment

          -  Brain metastases that are symptomatic or untreated or not stable for &gt;= 3 months
             (must be documented by imaging) or requiring corticosteroids; subjects on a stable
             dose of corticosteroids &gt; 1 month or who have been off corticosteroids for at least 2
             weeks can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP)
             medical monitor; subjects must also be off enzyme-inducing anticonvulsants for &gt; 4
             weeks

          -  History of acute coronary syndromes (including unstable angina), coronary
             angioplasty, or stenting within the past 24 weeks; class II, III, or IV heart failure
             as defined by the New York Heart Association (NYHA) functional classification system;
             or history of known cardiac arrhythmias unless it has been stably controlled

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to dabrafenib or other agents used in this study

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with dabrafenib

          -  Any condition or medical problem in addition to the underlying malignancy and organ
             dysfunction which the investigator feels would pose unacceptable risk
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Haluska</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Chung</last_name>
      <phone>626-471-9200</phone>
      <email>vchung@coh.org</email>
    </contact>
    <investigator>
      <last_name>Vincent Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California/Norris Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony El-Khoueiry</last_name>
      <phone>323-865-3595</phone>
      <email>elkhouei@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony El-Khoueiry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen L. Kelly</last_name>
      <phone>916-734-3735</phone>
      <email>karen.kelly@ucdmc.ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Karen L. Kelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope South Pasadena</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen C. Koehler</last_name>
      <phone>626-396-2900</phone>
      <email>skoehler@cohmg.com</email>
    </contact>
    <investigator>
      <last_name>Stephen C. Koehler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy O'Bryant</last_name>
      <phone>303-724-2625</phone>
      <email>cindy.obryant@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Cindy O'Bryant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George P. Kim</last_name>
      <phone>904-953-6460</phone>
      <email>kim.george@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>George P. Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle A. Rudek</last_name>
      <phone>410-614-6321</phone>
      <email>mrudek2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Michelle A. Rudek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey I. Shapiro</last_name>
      <phone>617-632-4942</phone>
      <email>geoffrey_shapiro@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey I. Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia M. LoRusso</last_name>
      <phone>313-576-8716</phone>
      <email>lorussop@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Patricia M. LoRusso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Haluska</last_name>
      <phone>507-284-2511</phone>
      <email>haluska.paul@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Haluska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer R. Eads</last_name>
      <phone>216-844-6031</phone>
      <email>jennifer.eads@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer R. Eads</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hussein A. Tawbi</last_name>
      <phone>412-648-6578</phone>
      <email>tawbhx@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Hussein A. Tawbi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William R. Schelman</last_name>
      <phone>608-263-6222</phone>
      <email>wrs@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>William R. Schelman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe L. Bedard</last_name>
      <phone>416-946-4534</phone>
      <email>philippe.bedard@unh.ca</email>
    </contact>
    <investigator>
      <last_name>Philippe L. Bedard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>July 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
